Abstract
Red blood cell (RBC) encapsulated L-asparaginase is a novel therapeutic for the treatment of asparagine auxotrophic malignancies. The enzyme-loaded red blood cells function as bioreactors to deplete bloodstream substrate. This delivery system provides improved pharmacodynamics with protection from circulating proteolytic enzymes and avoidance of early liver or renal clearance. The “drug” is manufactured with ABO and Rh compatible donor blood when a prescription is received. Because of the industrial scale manufacturing, the “drug” is transfused the day of receipt at the clinical site. Preliminary clinical studies show utility in childhood and adult acute lymphoblastic leukemia. Based on previous studies of applications in different diseases and assessment of different biomarkers, we propose this agent offers a safe and potentially effective treatment for a subset of chemotherapy refractory acute myeloid leukemia patients. The history, chemistry, biology, pharmacology, and relevant clinical experiences with L-asparaginase as well as the properties and proposed protocols with the red cell-encapsulated enzyme are reviewed.
Keywords: Red blood cell encapsulation, L-asparaginase and AML, Red blood cell (RBC), novel therapeutic, bloodstream, pharmacodynamics, proteolytic enzyme, leukemia, chemotherapy, pharmacology, encapsulated enzyme
Protein & Peptide Letters
Title:Red Blood Cell-Encapsulated L-Asparaginase: Potential Therapy of Patients with Asparagine Synthetase Deficient Acute Myeloid Leukemia
Volume: 20 Issue: 4
Author(s): Vaidehi Agrawal, Jung Hee Woo, Gautham Borthakur, Hagop Kantarjian and Arthur E. Frankel
Affiliation:
Keywords: Red blood cell encapsulation, L-asparaginase and AML, Red blood cell (RBC), novel therapeutic, bloodstream, pharmacodynamics, proteolytic enzyme, leukemia, chemotherapy, pharmacology, encapsulated enzyme
Abstract: Red blood cell (RBC) encapsulated L-asparaginase is a novel therapeutic for the treatment of asparagine auxotrophic malignancies. The enzyme-loaded red blood cells function as bioreactors to deplete bloodstream substrate. This delivery system provides improved pharmacodynamics with protection from circulating proteolytic enzymes and avoidance of early liver or renal clearance. The “drug” is manufactured with ABO and Rh compatible donor blood when a prescription is received. Because of the industrial scale manufacturing, the “drug” is transfused the day of receipt at the clinical site. Preliminary clinical studies show utility in childhood and adult acute lymphoblastic leukemia. Based on previous studies of applications in different diseases and assessment of different biomarkers, we propose this agent offers a safe and potentially effective treatment for a subset of chemotherapy refractory acute myeloid leukemia patients. The history, chemistry, biology, pharmacology, and relevant clinical experiences with L-asparaginase as well as the properties and proposed protocols with the red cell-encapsulated enzyme are reviewed.
Export Options
About this article
Cite this article as:
Agrawal Vaidehi, Hee Woo Jung, Borthakur Gautham, Kantarjian Hagop and E. Frankel Arthur, Red Blood Cell-Encapsulated L-Asparaginase: Potential Therapy of Patients with Asparagine Synthetase Deficient Acute Myeloid Leukemia, Protein & Peptide Letters 2013; 20 (4) . https://dx.doi.org/10.2174/0929866511320040003
DOI https://dx.doi.org/10.2174/0929866511320040003 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interaction of Biologically Active Amines with Mitochondria and Their Role in the Mitochondrial-Mediated Pathway of Apoptosis
Current Medicinal Chemistry Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design Mesenchymal Stromal Cells from Umbilical Cord Blood
Current Stem Cell Research & Therapy Novel Action and Mechanism of Auranofin in Inhibition of Vascular Endothelial Growth Factor Receptor-3-Dependent Lymphangiogenesis
Anti-Cancer Agents in Medicinal Chemistry Basis for Resistance to Imatinib in 16 BCR-ABL Mutants as Determined Using Molecular Dynamics
Recent Patents on Anti-Cancer Drug Discovery Dendritic Cells for Active Anti-Cancer Immunotherapy: Targeting Activation Pathways Through Genetic Modification
Endocrine, Metabolic & Immune Disorders - Drug Targets Advancements in Adjuvanticity of Bioactive Inorganic and Organic Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Survivin: Role in Normal Cells and in Pathological Conditions
Current Cancer Drug Targets Main Nutritional and Environmental Risk Factors in Children with Leukemia from a Public Hospital of the State of Guanajuato, Mexico
Current Cancer Therapy Reviews Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology Editorial (Hot Topic:Aspergillosis: New Insights into Disease, Diagnostic and Treatment)
Current Pharmaceutical Design Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Current Cancer Drug Targets Doxycycline as Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Antioxidant, Pro-Oxidant and Other Biological Activities of Sesquiterpenes
Current Topics in Medicinal Chemistry Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry Contrast Enhanced Sonography for Diagnosis of (Peri-) Splenic Pathology
Current Medical Imaging Chemistry and Biological Activity of [1,2,3]-Benzotriazine Derivatives
Current Organic Chemistry Synthesis and Bioactivity of (R)-Ricinoleic Acid Derivatives: A Review
Current Medicinal Chemistry Subject Index to Volume 10
Current Pharmaceutical Design